肿瘤细胞治疗研究
英文原题：Antibody-Based Therapies for Peripheral T-Cell Lymphoma.
尽管基于抗体的免疫治疗策略已彻底改变了 B 细胞淋巴瘤的治疗，但 T 细胞淋巴瘤的进展一直受制于靶点欠佳、疾病异质性以及有效治疗选择有限。
尽管基于抗体的免疫治疗策略已彻底改变B细胞淋巴瘤的治疗，T细胞淋巴瘤的治疗进展仍受靶点不理想、疾病异质性以及有效治疗选择有限等因素制约。尽管如此，近期对T细胞生物学认识的深化、新靶点的发现以及新疗法的出现，为未来带来了希望。本综述探讨外周T细胞淋巴瘤（PTCL）抗体治疗策略中四个当前及不断发展的领域：单克隆抗体（mAb）、双特异性抗体（BsAb）、CAR-T 细胞疗法（CAR-T）和抗体药物偶联物（ADC）。讨论中还将涉及这些策略的局限、经验教训及未来可能的发展方向。
While antibody-based immunotherapeutic strategies have revolutionized the treatment of B-cell lymphomas, progress in T-cell lymphomas has suffered from suboptimal targets, disease heterogeneity, and limited effective treatment options. Nonetheless, recent advances in our understanding of T-cell biology, the identification of novel targets, and the emergence of new therapies provide hope for the future. In this review, we explore four areas of current and evolving antibody-based strategies for the treatment of peripheral T-cell lymphoma (PTCL): monoclonal antibodies (mAbs), bispecific antibodies (BsAs), chimeric antigen receptor T-cell therapy (CAR-T), and antibody-drug conjugates (ADCs). As part of this discussion, we will also include limitations, lessons learned, and potential future directions.
MEMBER ACCOUNT
登录成功会直接打开下一页。
